RecruitingPhase 3NCT05275972

Descemet Endothelial Thickness Comparison Trial II

Descemet Endothelial Thickness Comparison Trials (DETECT I & II)


Sponsor

Stanford University

Enrollment

60 participants

Start Date

Jan 23, 2023

Study Type

INTERVENTIONAL

Conditions

Summary

Descemet Endothelial Thickness Comparison Trial (DETECT) II is a multi-center, outcome assessor-masked, placebo-controlled clinical trial randomizing 60 patients with Fuchs endothelial dystrophy to DMEK versus Descemet Stripping Only (DSO) with adjunctive Ripasudil.


Eligibility

Min Age: 18 Years

Plain Language Summary

Simplified for easier understanding

This clinical trial is studying a drug called Placebo and a drug called Ripasudil for people with fuchs, fuchs dystrophy, and other related conditions. The study is currently recruiting participants at 8 locations. People eligible for this study include aged 18 Years and older.

This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Interested in this trial?

Get notified about updates and connect with the research team.

Interventions

DRUGRipasudil

Topical Ripasudil 0.4%

DRUGPlacebo

Topical Placebo


Locations(8)

Stanford University

Palo Alto, California, United States

University of California Davis

Sacramento, California, United States

University of Miami

Palm Beach Gardens, Florida, United States

Dartmouth-Hitchcock Medical Center

Lebanon, New Hampshire, United States

Legacy Devers Eye Institute

Portland, Oregon, United States

Oregon Health & Science University

Portland, Oregon, United States

University of Pennsylvania

Philadelphia, Pennsylvania, United States

Wills Eye Hospital

Philadelphia, Pennsylvania, United States

View Full Details on ClinicalTrials.gov

For the most up-to-date information, visit the official listing.

Visit

NCT05275972


Related Trials